Table 1 The summary statistics for 18 meta-analyses carried out by the MAG.
Meta-analysis | # trials | Q, P-value |
| Fixed Effect HR (CI) P-value |
|---|---|---|---|---|
cervix 1 [15] | 18 | 44.48, 0.00 | 62 | 1.05 (0.93-1.19) 0.39 |
cervix 2 [17] | 18 | 20.83 0.23 | 18 | 0.76 (0.67-0.85) 0.00 |
cervix 3 [15] | 5 | 9.18, 0.06 | 56 | 0.65 (0.53-0.80) 0.00 |
bladder 1 [14] | 9 | 7.27, 0.51 | 0 | 0.91 (0.83-1.01) 0.08 |
bladder 2 [16] | 6 | 2.25, 0.81 | 0 | 0.75 (0.60-0.96) 0.02 |
nsclc 1 [8] | 17 | 28.98, 0.02 | 45 | 1.04 (0.96-1.12) 0.33 |
nsclc 2 [8] | 7 | 3.63, 0.73 | 0 | 0.98 (0.83-1.14) 0.76 |
nsclc 3 [8] | 25 | 22.32, 0.56 | 0 | 0.90 (0.83-0.97) 0.01 |
nsclc 4 [8] | 11 | 39.63, 0.00 | 75 | 0.84 (0.74-0.95) 0.01 |
ovarian 1 [7] | 19 | 21.92, 0.24 | 18 | 0.98 (0.91-1.06) 0.69 |
ovarian 2 [7] | 11 | 12.83, 0.23 | 22 | 0.93 (0.83-1.05) 0.23 |
ovarian 3 [10] | 9 | 14.78, 0.06 | 46 | 0.88 (0.79-0.98) 0.02 |
ovarian 4 [10] | 9 | 10.35, 0.24 | 23 | 0.91 (0.80-1.05) 0.21 |
ovarian 5 [10] | 12 | 2.57, 1.00 | 0 | 1.02 (0.93-1.12) 0.66 |
port [11] | 9 | 13.06, 0.11 | 39 | 1.21 (1.08-1.34) 0.00 |
sarcoma [9] | 14 | 11.80, 0.54 | 0 | 0.89 (0.76-1.03) 0.12 |
oeso [12] | 6 | 10.37, 0.07 | 52 | 0.89 (0.78-1.01) 0.06 |
glioma [13] | 12 | 13.29, 0.27 | 17 | 0.85 (0.78-0.92) 0.00 |
(%)